By PTI Mar 12 2015 , New Delhi
Natco Pharma has received approval from the national drug regulator for generic sofosbuvir tablets that are used to treat hepatitis C.
The company has received approval for generic sofosbuvir tablets in the strength of 400 mg from Drugs Controller General (India), Natco Pharma said in a filing to the BSE.
"Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India," it added.
The company plans to sell the generic drug at retail price of Rs 19,900 per bottle of 28 tablets and expects to launch the product in India very soon, Natco Pharma said.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
The company had recently signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
Natco Pharma shares were trading 14.7 per cent up at Rs 2,056 apiece during pre-close session on the BSE.
"Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India," it added.
The company plans to sell the generic drug at retail price of Rs 19,900 per bottle of 28 tablets and expects to launch the product in India very soon, Natco Pharma said.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
The company had recently signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
Natco Pharma shares were trading 14.7 per cent up at Rs 2,056 apiece during pre-close session on the BSE.
No comments:
Post a Comment